102 related articles for article (PubMed ID: 2732024)
21. Ginkgolides and platelet-activating factor binding sites.
Hosford DJ; Domingo MT; Chabrier PE; Braquet P
Methods Enzymol; 1990; 187():433-46. PubMed ID: 2172741
[No Abstract] [Full Text] [Related]
22. Influence of the specific antagonist of PAF-acether, BN 52021, and of Ginkgo extract on the rejection of murine tail skin allografts and the PAF-acether mortality in mice in particular consideration of the role of TXB2.
Becker K; Braquet P; Förster W
Biomed Biochim Acta; 1988; 47(10-11):S165-8. PubMed ID: 3073760
[TBL] [Abstract][Full Text] [Related]
23. Cellular electrophysiological effects of platelet-activating factor (PAF) and its antagonist BN 52021 in cardiac preparations.
Kecskemeti V; Braquet P
Drugs Exp Clin Res; 1992; 18(1):9-16. PubMed ID: 1600866
[TBL] [Abstract][Full Text] [Related]
24. The alkyl-ether phospholipid platelet-activating factor is a stimulator of the hypothalamic-pituitary-adrenal axis in the rat.
Bernardini R; Calogero AE; Ehrlich YH; Brucke T; Chrousos GP; Gold PW
Endocrinology; 1989 Aug; 125(2):1067-73. PubMed ID: 2546734
[TBL] [Abstract][Full Text] [Related]
25. Involvement of platelet-activating factor (PAF) in endotoxin-induced intestinal motor disturbances in rats.
Pons L; Droy-Lefaix MT; Braquet P; Buéno L
Life Sci; 1989; 45(6):533-41. PubMed ID: 2570338
[TBL] [Abstract][Full Text] [Related]
26. Involvement of eicosanoids in platelet-activating factor-induced modulation of adenylyl cyclase activity in alveolar macrophages.
Beusenberg FD; van Schaik A; van Amsterdam JG; Bonta IL
J Lipid Mediat; 1991; 3(3):301-9. PubMed ID: 1663403
[TBL] [Abstract][Full Text] [Related]
27. Platelet-activating factor: an endogenous mediator of mesenteric ischemia-reperfusion-induced shock.
Mózes T; Braquet P; Filep J
Am J Physiol; 1989 Oct; 257(4 Pt 2):R872-7. PubMed ID: 2802004
[TBL] [Abstract][Full Text] [Related]
28. PAF increases vascular permeability in selected tissues: effect of BN-52021 and L-655,240.
Sirois MG; Jancar S; Braquet P; Plante GE; Sirois P
Prostaglandins; 1988 Nov; 36(5):631-44. PubMed ID: 3238010
[TBL] [Abstract][Full Text] [Related]
29. Action of platelet-activating factor (PAF) antagonists on the bronchopulmonary effects of PAF in the guinea-pig.
Pons F; Touvay C; Lejeune V; Carré C; Vilain B; Broquet C; Mencia-Huerta JM; Braquet P
J Lipid Mediat; 1989; 1(6):329-40. PubMed ID: 2519901
[TBL] [Abstract][Full Text] [Related]
30. Influence of the specific antagonist of PAF-acether, BN 52021, on the rejection of murine tail skin allografts and the PAF-acether mortality in mice in particular consideration of the role of TXB2.
Becker K; Lueddeckens G; Braquet P; Förster W
Prog Clin Biol Res; 1989; 301():499-503. PubMed ID: 2798460
[No Abstract] [Full Text] [Related]
31. Platelet-activating factor in organ transplant rejection.
Foegh ML; Chambers E; Khirabadi BS; Nakanishi T; Ramwell PW
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():377-82. PubMed ID: 2526501
[No Abstract] [Full Text] [Related]
32. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L.
Braquet P
Adv Prostaglandin Thromboxane Leukot Res; 1986; 16():179-98. PubMed ID: 2949548
[No Abstract] [Full Text] [Related]
33. Specific receptor sites for PAF in iris and ciliary body of the rabbit eye.
van Delft JL; van Haeringen NJ; Verbeij NL; Domingo MT; Chabrier PE; Braquet P
Curr Eye Res; 1988 Nov; 7(11):1063-8. PubMed ID: 2854038
[TBL] [Abstract][Full Text] [Related]
34. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021.
Braquet P; Guinot P; Touvay C
Agents Actions Suppl; 1987; 21():97-117. PubMed ID: 3314418
[No Abstract] [Full Text] [Related]
35. Inhibition of the alkali burn-induced lipoxygenation of arachidonic acid in the rabbit cornea in vivo by a platelet activating factor antagonist.
Bazan HE; Braquet P; Reddy ST; Bazan NG
J Ocul Pharmacol; 1987; 3(4):357-65. PubMed ID: 3141539
[TBL] [Abstract][Full Text] [Related]
36. Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity.
Dos Santos OF; Boim MA; Barros EJ; Schor N
Kidney Int; 1991 Oct; 40(4):742-7. PubMed ID: 1745025
[TBL] [Abstract][Full Text] [Related]
37. Cardiac ultrastructural effects of the platelet-activating factor and its antagonist BN 52021.
Kecskeméti V; Balogh I
Exp Toxicol Pathol; 1995 Dec; 47(6):463-70. PubMed ID: 8871085
[TBL] [Abstract][Full Text] [Related]
38. Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021.
Kecskemeti V; Balogh I
Transplant Proc; 1995 Oct; 27(5):2819-20. PubMed ID: 7482928
[No Abstract] [Full Text] [Related]
39. Effects of the platelet-activating factor antagonist BN 52021 on anti-islet cytotoxicity of mononuclear cells and serum from type 1 (insulin-dependent) diabetic patients.
Köhler E; Varnai G; Knospe S; Förster W; Michaelis D; Wanka H
Int Arch Allergy Appl Immunol; 1991; 95(4):352-5. PubMed ID: 1959976
[TBL] [Abstract][Full Text] [Related]
40. Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist.
Braquet P; Bourgain RH
Adv Exp Med Biol; 1987; 215():215-35. PubMed ID: 3314403
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
